Zoey Becker

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry.

After the University of Pennsylvania and the U.S. National Institutes of Health (NIH) separately pressed BioNTech for royalties on its Pfizer-partnered

PharmaEssentia is looking to expand the reach of its FDA-approved rare blood cancer treatment Besremi to another rare blood disorder after reviewing encouraging results from a phase 3 study.

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry.

The first day of the J.P. Morgan Healthcare Conference is in the books, featuring high-profile deal announcements from Johnson & Johnson, Eli Lilly, GSK and several other biopharma players.

Pfizer's latest-generation pneumococcal conjugate vaccine is in line to reach more people in Latin America and the Caribbean through a joint effort with Argentina's government, The Pan American Health Organization (PAHO) and Argentinian drugmaker Sinergium Biotech.

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry.

With just over 100 days as CEO now under her belt, Catherine Owen Adams is looking to cruise rare disease-focused Acadia Pharmaceuticals into its first $1 billion sales year.

After hitting a regulatory roadblock in 2022, Sanofi's consumer healthcare business Opella has secured the FDA's blessing to move forward with its ambition to convert its erectile dysfunction med Cialis into an over-the-counter product.

Fosun International's proposed buyout of its partially owned subsidiary, Shanghai Henlius Biotech, has been quashed, with the necessary threshold of Henlius' shareholders not voting in favor of the deal.